These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 21530171)

  • 1. A framework for applying unfamiliar trial designs in studies of rare diseases.
    Gupta S; Faughnan ME; Tomlinson GA; Bayoumi AM
    J Clin Epidemiol; 2011 Oct; 64(10):1085-94. PubMed ID: 21530171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal designs for estimating the interesting part of a dose-effect curve.
    Miller F; Guilbaud O; Dette H
    J Biopharm Stat; 2007; 17(6):1097-115. PubMed ID: 18027219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian adaptive biased-coin designs for clinical trials with normal responses.
    Atkinson AC; Biswas A
    Biometrics; 2005 Mar; 61(1):118-25. PubMed ID: 15737084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A practical guide to Bayesian group sequential designs.
    Gsponer T; Gerber F; Bornkamp B; Ohlssen D; Vandemeulebroecke M; Schmidli H
    Pharm Stat; 2014; 13(1):71-80. PubMed ID: 24038922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Adaptive designs for clinical trial].
    Li W; He SJ; Wang Y; Cheng XR; Jia X
    Zhonghua Liu Xing Bing Xue Za Zhi; 2007 Jun; 28(6):605-7. PubMed ID: 17939395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementing a decision-theoretic design in clinical trials: why and how?
    Palmer CR; Shahumyan H
    Stat Med; 2007 Nov; 26(27):4939-57. PubMed ID: 17582801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trials and haemophilia: does the Bayesian approach make the ideal and desirable good friends?
    Iorio A; Marcucci M
    Haemophilia; 2009 Jul; 15(4):900-3. PubMed ID: 19473413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seamless phase II/III designs.
    Stallard N; Todd S
    Stat Methods Med Res; 2011 Dec; 20(6):623-34. PubMed ID: 20724313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative designs for clinical trials in rare diseases.
    Abrahamyan L; Feldman BM; Tomlinson G; Faughnan ME; Johnson SR; Diamond IR; Gupta S
    Am J Med Genet C Semin Med Genet; 2016 Dec; 172(4):313-331. PubMed ID: 27862920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining proof-of-concept with dose-finding: utilization of adaptive designs in migraine clinical trials.
    Sagkriotis A; Scholpp J
    Cephalalgia; 2008 Aug; 28(8):805-12. PubMed ID: 18513264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptive design in clinical research: issues, opportunities, and recommendations.
    Chang M; Chow SC; Pong A
    J Biopharm Stat; 2006 May; 16(3):299-309; discussion 311-2. PubMed ID: 16724486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of draft FDA adaptive design guidance.
    Cook T; DeMets DL
    J Biopharm Stat; 2010 Nov; 20(6):1132-42. PubMed ID: 21058109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trials and rare diseases.
    Gerss JW; Köpcke W
    Adv Exp Med Biol; 2010; 686():173-90. PubMed ID: 20824446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive methods: when and how should they be used in clinical trials?
    Porcher R; Lecocq B; Vray M;
    Therapie; 2011; 66(4):319-26, 309-17. PubMed ID: 21851793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical Bayesian design and analysis for drug and device clinical trials.
    Hobbs BP; Carlin BP
    J Biopharm Stat; 2008; 18(1):54-80. PubMed ID: 18161542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase II designs in cancer clinical trials: current status and future directions.
    Lee JJ; Feng L
    J Clin Oncol; 2005 Jul; 23(19):4450-7. PubMed ID: 15994154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient ways exist to obtain the optimal sample size in clinical trials in rare diseases.
    van der Lee JH; Wesseling J; Tanck MW; Offringa M
    J Clin Epidemiol; 2008 Apr; 61(4):324-30. PubMed ID: 18313556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A framework for planning and critiquing medication compliance and persistence research using prospective study designs.
    Gwadry-Sridhar FH; Manias E; Zhang Y; Roy A; Yu-Isenberg K; Hughes DA; Nichol MB
    Clin Ther; 2009 Feb; 31(2):421-35. PubMed ID: 19302915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sample-size calculations for trials that inform individual treatment decisions: a 'true-choice' approach.
    Girling AJ; Lilford RJ; Braunholtz DA; Gillett WR
    Clin Trials; 2007; 4(1):15-24. PubMed ID: 17327242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.